Company intelligence / Profile preview
Abintus Bio
San Diego, California, United Statesabintusbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Developing in vivo CAR-X products that simultaneously target both adaptive and innate immune effector cells to produce immune responses against tumors. Initial products were poised to enter clinical evaluation as early as 2023.
- Therapeutic areas
- OncologyRare DiseasesImmunologyInfectious Diseases
- Modalities
- In vivo CAR-X productsgenetic medicines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Memorial Sloan Kettering Cancer Center
Beyond the preview
Go deeper on Abintus Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Abintus Bio.